Alert detail
FDA Approval: TRUXIMA (RITUXIMAB-ABBS) — Type 5 - New Formulation or New Manufacturer
Policy ID: FDA-BLA761088Specialty: OncologyAdded: 7/8/2026Effective: 2018-11-28billing update
What changed
New FDA drug approval. Coverage and billing pathway depend on the FDA label and applicable Medicare LCDs/NCDs — for very recent approvals the label may not be posted yet. Verify against the FDA label and current coverage policy before billing.
Who’s affected: Oncology billing teams · Effective: 2018-11-28
Affected codes
CodesJ9312
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 1 billing code.
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.